Enanta Pharmaceuticals ENTA
NASDAQ ENTA
$14.08 +0.06 (+0.43%)
As of: Sep 4, 2026 · 3:59 PM EDT

Enanta Pharmaceuticals (ENTA) EBIT Margin Growth (5y) (2017 - 2026)

Analysis

Enanta Pharmaceuticals (ENTA) EBIT Margin Growth (5y) (2017 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Enanta Pharmaceuticals 409.30 Mn 219.79 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 3,649.00
Mar 31, 2026 7,845.00
Dec 31, 2025 -2,171.00
Sep 30, 2025 -3,784.00
Jun 30, 2025 1,935.00
Mar 31, 2025 -12,133.00
Dec 31, 2024 -16,331.00
Sep 30, 2024 -21,691.00
Jun 30, 2024 -14,304.00
Mar 31, 2024 -18,884.00
Dec 31, 2023 -23,364.00
Sep 30, 2023 -21,517.00
Jun 30, 2023 -23,387.00
Mar 31, 2023 -25,997.00
Dec 31, 2022 -16,498.00
Sep 30, 2022 -20,464.00
Jun 30, 2022 775.00
Mar 31, 2022 -7,474.00
Dec 31, 2021 -4,235.00
Sep 30, 2021 -11,893.00